Bayer (BAYRY) announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone. Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 90 countries worldwide, including China, Europe, Japan and the United States. It is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block the harmful eff ...

Bayer (BAYRY) announces the initiation of the phase II, ALPINE-1 study, on pipeline candidate BAY3283142 following the successful first-in-human trials. BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, is being evaluated for patients with chronic kidney disease (CKD). APLINE-1 is a randomized, double-blind, placebo-controlled, multicenter study that will assess the efficacy and safety of BAY3283142 in CKD patients. CKD is a progressive condition affecting more than 10% of the global ...

Key Takeaways A U.S. appeals court ruled in favor of Bayer-owned Monsanto in a lawsuit alleging the company failed to warn customers about the cancer risk of its Roundup weed killer. The court said state labeling requirements cannot usurp federal ones, and the Environmental Protection Agency (EPA) did not require a cancer warning on Roundup. The decision conflicts with those from other courts, and the company argued that the U.S. Supreme Court should settle the issue. In a big victory for Bayer-owned Monsan ...

CHICAGO, ILLINOIS - MAY 14: Roundup weed killing products are offered for sale at a home improvement store on May 14, 2019 in Chicago, Illinois. A jury yesterday ordered Monsanto, the maker of Roundup, to pay a California couple more than $2 billion in damages after finding that the weed killer had caused their cancer. This is the third jury to find Roundup had caused cancer since Bayer purchased Monsanto about a year ago. Bayer's stock price has fallen more than 40 percent since the takeover. (Photo by Sco ...

JHVEPhoto One of my investments that was a huge disappointment in the recent past was the German life science company Bayer Aktiengesellschaft (OTCPK:BAYZF). Of course, one could argue that Bayer investors are now used to disappointments as the stock is now declining for almost 10 years and every time when investors assumed it couldn't get any worse, terrible new news came up and the stock was continuing to decline. My last article about Bayer was published about three months ago following first quarter res ...

Fotofantastika Dear readers/followers, I've been very careful about pharma company Bayer (OTCPK:BAYRY) since my last article. You can find that particular article here. When I last wrote about Bayer, the company had just cut the dividend to the bone (less than 1% at the time of publishing of that piece). It's fair to say that the fortunes for Bayer have turned around over the past 3 years and that there's according to the valuation not much reason for near-term optimism to be had here. The cases to be made ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Jost Reinhard - IR William N. Anderson - Chairman & CEO Wolfgang U. Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Conference Call Participants Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Sachin Jain - Bank of America Christian Faitz - Kepler Cheuvreux Emily F ...

Bayer AG (BAYRY) reported second-quarter 2024 core earnings of 25 cents per American Depositary Receipt (ADR), on par with the Zacks Consensus Estimate. The company reported earnings of 33 cents per ADR in the year-ago quarter. Core earnings of €0.94 per share deteriorated 23% year over year due to a decline in earnings at the Crop Science Division. Total sales in the reported quarter were $12 billion (€11.14 billion), up 0.9% on a reported basis as volume growth of 1.6% and positive pricing impact of 1.5% ...

///////////// Health for all, Hunger for none Q2 2024 Investor Call A u g u s t 0 6 , 2 0 2 4 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Thes ...

Per the data readout, the combo therapy of darolutamide and ADT significantly increased rPFS compared with placebo plus ADT. Treatment with the investigational combo was overall well tolerated and demonstrated a safety profile that was consistent with that observed in previously completed studies in advanced prostate cancer. Image Source: Zacks Investment Research Subject to approval, the company will be able to cater to individual mHSPC patient needs by tailoring customized darolutamide/ADT treatment plans ...